Quartet Lead and Resynchronization Therapy Options (QUARTO)

February 1, 2019 updated by: Abbott Medical Devices

QUARTET LEAD AND RESYNCHRONIZATION THERAPY OPTIONS To Investigate the Stimulatory Possibilities Offered by the Different Configurations Available for the Quartet Lead and Their Effect on Haemodynamic and Clinical Response.

The purpose of this Clinical Trial is to determine the percentage of patients whose hemodynamic response improves with the different configurations offered by the new Quartet® left ventricular lead, as a result of its four electrodes, with respect to the configurations offered by a standard bipolar lead.

Furthermore, the optimal stimulation configuration will be determined from a comparison with traditional configurations.

Study Overview

Status

Completed

Conditions

Detailed Description

This is a prospective, non-randomised, multi-centre, national, interventional clinical trial of a medical device.

This trial involves two visits: one at the beginning of the study, which will be undertaken in the seven days following implant, and another visit at 6 months after enrollment. It is recommended that the enrollment visit is undertaken as soon as possible after implantation, although the time window allows the timing to be adapted to each centre's standard practice. Resynchronization therapy in those patients suitable for participation in this trial is expected to begin once this enrollment visit has been completed.

Once data collection at enrollment visit has been completed, final device programming will be based on each investigator's criteria and will be undertaken following the standard practice of each centre.

Study Type

Interventional

Enrollment (Actual)

51

Phase

  • Phase 4

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

      • Málaga, Spain, 29010
        • Hospital Clinico Universitario Virgen de la Victoria

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

18 years and older (ADULT, OLDER_ADULT)

Accepts Healthy Volunteers

No

Genders Eligible for Study

All

Description

Inclusion Criteria:

  1. Patients with a Cardiac resynchronization Therapy Defibrillator device (CRT-D) and a Quartet® quadripolar electrode from St Jude Medical (used in "Single Site Pacing" mode) implanted in the left ventricle.
  2. Patients who have provided written informed consent
  3. Patients who are in sinus rhythm.
  4. Patients older than 18 years of age.

Exclusion Criteria:

  1. Patients in atrial fibrillation at the time of the echocardiographic study of the enrollment visit.
  2. Patients with valvular disease.
  3. Patients in functional class New York Heart Association (NYHA) IV
  4. Patients for whom echocardiography images suitable for determining the cardiac output cannot be obtained.
  5. Patients whose device has been changed/upgraded.
  6. Pregnant patients.
  7. Patients who do not fulfill all the inclusion criteria.
  8. Patients who are unable to provide written informed consent

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: SUPPORTIVE_CARE
  • Allocation: NA
  • Interventional Model: SINGLE_GROUP
  • Masking: NONE

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
NO_INTERVENTION: CRT therapy
Cardiac Resynchronization Therapy Defibrillator (CRT-D)
Cardiac Resynchronization Therapy Defibrillator
Other Names:
  • Promote Q. Model
  • Promote Quadra™.
  • Quartet®: Tetrapolar left ventricular lead. Model 1458Q.

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Time Frame
Number of Patients Whose Cardiac Output (CO) Value in Acute, as Measured Echocardiographically, Improves With the Different Stimulation Vectors Offered by the Quartet® Left Ventricular Electrode.
Time Frame: Enrollment visit (in the seven days after implantation of the device)
Enrollment visit (in the seven days after implantation of the device)

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Percent Difference Between the Best CO From Non-traditional Vectors and Best CO From Traditional Vectors
Time Frame: At enrollment

In patients with best CO obtained from Non-traditional, to calculate the percent difference between the best CO from Non-traditional vectors and best CO from Traditional vectors, vectors.This percentage was the CO from Non-traditional vectors minus CO from Traditional vectors then divided by CO from Traditional vectors.

The Quartet® lead has 4 poles: Distal (D1), Mid 2 (M2), Mid 3 (M3) and Proximal (P4). The 3 Traditional vectors are the traditional configurations available in a standard bipolar lead: D1-M2, D1-Right Ventricular Coil (RVC) and M2-RVC. The 7 Non-traditional vectors are the additional configurations available in a Quartet® lead: D1-P4, M2-P4, M3-M2, M3-RVC, M3-P4, P4-M2 and P4-RVC.

At enrollment
Cardiac Output (CO) With Different Configurations at Enrollment
Time Frame: Enrollment visit (in the seven days after implantation of the device)
Means of baseline non-paced CO, best CO obtained from traditional configurations and best CO obtained from all quadripolar configurations at enrollment.
Enrollment visit (in the seven days after implantation of the device)
Capture Threshold
Time Frame: Enrollment visit (in the seven days after implantation of the device)

Capture and phrenic threshold data will be recorded for each of the stimulation vectors studied.

Attempts will also be made to avoid phrenic stimulation in those patients who suffer from it, whilst maintaining good capture thresholds, by changing between the new configurations offered by the Quartet® electrode.

Enrollment visit (in the seven days after implantation of the device)
Capture Threshold
Time Frame: 6 months post-implant

Capture and phrenic threshold data will be recorded for each of the stimulation vectors studied.

Attempts will also be made to avoid phrenic stimulation in those patients who suffer from it, whilst maintaining good capture thresholds, by changing between the new configurations offered by the Quartet® electrode.

6 months post-implant
Number of Vectors With Phrenic Nerve Stimulation (PNS)
Time Frame: Enrollment visit (in the seven days after implantation of the device)

Capture and phrenic threshold data will be recorded for each of the stimulation vectors studied.

Attempts will also be made to avoid phrenic stimulation in those patients who suffer from it, while maintaining good capture thresholds, by changing between the new configurations offered by the Quartet® electrode.

Enrollment visit (in the seven days after implantation of the device)
Number of Vectors With Phrenic Nerve Stimulation (PNS)
Time Frame: At 6 months

Capture and phrenic threshold data will be recorded for each of the stimulation vectors studied.

Attempts will also be made to avoid phrenic stimulation in those patients who suffer from it, whilst maintaining good capture thresholds, by changing between the new configurations offered by the Quartet® electrode.

At 6 months
Number of Patients With PNS in All Vectors
Time Frame: At enrollment
To calculate the number of patients that exhibit PNS in all traditional vector
At enrollment
Number of Patients With PNS in All Vectors, That Could be Avoided With a Non-traditional Vector
Time Frame: At enrollment
To calculate the number of patients, who exhibit PNS in all traditional vector, in which PNS could be avoided using a non-traditional vector
At enrollment
Number of Patients With PNS in All Vectors
Time Frame: At 6 months
To calculate the number of patients that exhibit PNS in all traditional vector
At 6 months
Number of Patients With PNS in All Vectors, That Could be Avoided With a Non-traditional Vector
Time Frame: At 6 months
To calculate the number of patients, who exhibit PNS in all traditional vector, in which PNS could be avoided using a non-traditional vector
At 6 months

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Investigators

  • Principal Investigator: Dr. Francisco Javier Alzueta Rodríguez, PhD, Hospital Clinico Universitario Virgen de la Victoria

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start

January 1, 2011

Primary Completion (ACTUAL)

April 1, 2012

Study Completion (ACTUAL)

September 1, 2012

Study Registration Dates

First Submitted

February 3, 2011

First Submitted That Met QC Criteria

February 10, 2011

First Posted (ESTIMATE)

February 15, 2011

Study Record Updates

Last Update Posted (ACTUAL)

February 20, 2019

Last Update Submitted That Met QC Criteria

February 1, 2019

Last Verified

February 1, 2019

More Information

Terms related to this study

Additional Relevant MeSH Terms

Other Study ID Numbers

  • CR 10-046-SP-HF

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Heart Failure

Clinical Trials on Cardiac Resynchronization Therapy Defibrillator

Subscribe